Anavex Life Sciences CORP Form 4 insider transactions

ANAVEX LIFE SCIENCES CEO Christopher U. Missling's stock options for 125,000 shares vested following the achievement of a key performance milestone related to blarcamesine's regulatory dialogue.

ANAVEX LIFE SCIENCES CORP.'s Principal Financial Officer, Sandra Boenisch, saw 12,500 stock options vest following the achievement of a key regulatory milestone for blarcamesine.

ANAVEX Life Sciences' PFO & Treasurer, Sandra Boenisch, saw 12,500 stock options vest following the successful readout of the AV3-71-SZ-001 schizophrenia study.

ANAVEX LIFE SCIENCES CORP. CEO Christopher Missling's stock options for 125,000 shares vested following the successful readout of the AV3-71-SZ-001 schizophrenia study.

Anavex Life Sciences Corp.'s President and CEO, Christopher U. Missling, exercised 187,500 stock options, resulting in a net acquisition of 42,452 shares after tax withholdings.

ANAVEX LIFE SCIENCES CORP.'s PFO & Treasurer, Sandra Boenisch, saw 12,500 stock options vest following the achievement of a key preclinical data publication milestone.

Anavex Life Sciences CEO Christopher Missling's stock options for 125,000 shares vested following the achievement of a key performance milestone related to preclinical blarcamesine data.

Anavex Life Sciences Director Thomas Steffen exercised stock options and increased his direct beneficial ownership of common stock through a net exercise.

Sandra Boenisch, PFO & Treasurer of Anavex Life Sciences Corp., acquired 12,500 shares of common stock through option vesting related to a performance milestone.

Christopher Missling, CEO of Anavex Life Sciences, exercised stock options for 125,000 shares after a performance milestone was met in the ANAVEX3-71 Phase 2 clinical trial for Schizophrenia.

Peter Donhauser, a director of Anavex Life Sciences Corp., reports the acquisition of stock options.

Director Jiong Ma reports acquisition of stock options in Anavex Life Sciences Corp.

Athanasios Skarpelos, a director of Anavex Life Sciences Corp., reports the acquisition of stock options.

Director Thomas Steffen reports acquisition of 50,000 Anavex Life Sciences Corp. stock options.

Claus van der Velden, a director of Anavex Life Sciences Corp., reports the acquisition of stock options.

Christopher Missling, CEO of Anavex Life Sciences, exercised stock options and sold a portion of the acquired shares to cover the exercise price and tax withholdings.

Anavex Life Sciences CEO, Christopher Missling, exercised stock options after the company met performance milestones related to Alzheimer's disease studies.

Anavex Life Sciences Corp.'s PFO & Treasurer, Sandra Boenisch, exercised stock options for 12,500 shares after a performance milestone was met.

Anavex Life Sciences Corp.'s PFO & Treasurer, Sandra Boenisch, exercised stock options for 12,500 shares after a performance milestone was met.

Anavex Life Sciences CEO, Christopher Missling, exercised stock options for 125,000 shares after a performance milestone was met.

Anavex Life Sciences CEO, Christopher Missling, had 125,000 stock options vest due to a performance milestone being met.

Anavex Life Sciences' PFO and Treasurer, Sandra Boenisch, vested 10,000 shares of common stock due to the achievement of a performance milestone related to the Phase 2a/b AD-004 Alzheimer's disease study.

Director Peter Donhauser reports purchasing 2,835 shares of Anavex Life Sciences Corp. at $3.64 per share on June 14, 2024.

Director Steffen Thomas purchased 5,000 shares of Anavex Life Sciences Corp. on May 15, 2024.

Anavex Life Sciences Corp. CEO Christopher Missling exercised stock options and sold shares on March 28, 2024.